| Característica |
Objectiu de la convocatòria
This competitive program supports independent quality improvement initiatives aimed at optimizing and standardizing routine clinical practice for patients with multiple myeloma. Its objective is to enhance health outcomes and quality of life for patients receiving bispecific antibodies by improving the use of existing healthcare services, tools, and care pathways, or by optimizing local care processes.
|
Característiques principals
Clinical Area: Oncology - Multiple Myeloma
Projects should focus on:
Ensuring continuity of care across inpatient and outpatient settings
Caregiver readiness and support programs
Primary and specialty care integration programs, and data-driven projects for systematic improvement at the local or national level
Robust processes for adverse event (AE) management and reporting, including CRS, ICANS, and infections
Mentorship networks between academic and community centers to optimize patient selection and therapy management
Innovative communication strategies among care teams
Technology solutions such as remote monitoring to improve patient outcomes
Approaches to guarantee equitable access to BsAb regardless of geography or socioeconomic status
|
Lloc de presentació
HMRIB and PSMAR staff who need more information should contact:
Research Grants and Contracts Office. C/ Doctor Aiguader, 88. 08003 Barcelona. Tel.: 93.316.04.00.
Carol Barnwell: [email protected] Ext.: 1670
Marta López: [email protected] Ext.: 1576
Júlia Vidal: [email protected] Ext.: 1736
|
Convocatòria (URL)
https://cdn.pfizer.com/pfizercom/2026-03/2026-ONC-ES-OptimalClinicalCareMultipleMyeloma-QI.pdf
|
Requisits
The geographical scope is limited to Spain.
Eligible institutions are healthcare institutions, professional associations, medical societies, and patient advocacy groups (PAGs) involved in the care of MM patients.
Only organizations can receive grants; individuals are not eligible.
Collaborations are encouraged, both within a single institution and across multiple organizations, provided all partners have relevant roles and the requesting organization plays a key role.
The applicant must be the project/program lead—or an authorized designee—and must be an employee or contractor of the requesting organization.
For projects offering continuing education credit, the requesting organization must be accredited.
Clinical research projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.
|
Dotació
€20,000–40,000
|
Durada
18 months, beginning in September 2026.
|